As she hopped off the bleachers onto the grass after a graduation ceremony, Elizabeth Zarrella felt an unfamiliar pain in her back. A visit to the emergency room a week later revealed the source of the pain and the reason for its severity: her vertebrae were so brittle that two of them had been compressed … Read more
In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors. Although these drugs have shown effectiveness in Hodgkin lymphoma, lung cancer, bladder cancer, kidney cancer, and nearly a dozen other malignancies, their track record against colorectal cancer has been lackluster, particularly for patients with the most common subtype of … Read more
Bladder cancer treatment is advancing, with several approved immunotherapy options, an approved gene therapy, and an approach to cell therapy planned for testing in clinical trials at Dana-Farber. What is bladder cancer? The most common form of bladder cancer is urothelial carcinoma, in which the urothelial cells that line the bladder and urinary tract begin … Read more
Research by Dana-Farber scientists shows cancer cells can use the TREX1 protein to silence genes that might summon an immune system attack on the cells.
Nancy Arsenault was taking a lunch break from driving her elementary school bus route in her hometown of Stow, Massachusetts, when she began to experience double vision. She had been first diagnosed with pre-invasive breast cancer in 2006, which recurred in 2011. In 2019, she developed an invasive breast cancer in her chest wall and … Read more
To understand the genesis of the bone marrow transplant field, go back to the detonation, in 1945, of the first nuclear weapons and the shadow of the Atomic Age. The search for ways to rescue the blood-forming and immune systems of individuals exposed to high doses of radiation provided the impetus for donor bone marrow … Read more
Natural killer (NK) cells are white blood cells that serve as a part of the body’s first line of defense against infections and cancers. Along with T cells and B cells, NK cells have specialized roles as part of the immune system and have shown potential for being used in cancer immunotherapy. Their effectiveness is still being … Read more
Non-small cell lung cancers (NSCLCs) that are most loaded with genetic mutations are most susceptible to immunotherapy drugs known as PD-L1 inhibitors, a new study by Dana-Farber researchers shows. The study, published recently in JAMA Oncology, can help doctors identify patients with the disease who are likely to benefit from the drugs, which foil tumors’ … Read more
Mark Signer uses his voice to raise awareness about anaplastic thyroid cancer — something he thought impossible two years ago. When he was diagnosed with this highly aggressive cancer in July 2020, he was told to get his affairs in order. And when he awoke from the surgery that removed his tumor, he couldn’t speak; … Read more
The results of the phase 2 clinical trial would have been impressive even if they didn’t involve a particularly stubborn form of cancer. In the trial, led by Dana-Farber’s Jonathan Schoenfeld, MD, MPH, 29 patients with locally advanced squamous cell cancer of the oral cavity were treated with one or two immune checkpoint inhibitors — … Read more
Results of several phase 3 trials and dozens of other studies led by Dana-Farber researchers were presented online and in person June 3-7 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting. Some of the research reports presented by Dana-Farber investigators include: Improved progression-free … Read more
Stephan Bunker has learned to be prepared for anything during a half-century protecting others as a soldier, volunteer firefighter, law enforcement official, and director of 911 dispatchers for the state of Maine. So when Bunker was the one facing an emergency — a diagnosis of a brain cancer known as primary central nervous system (CNS) … Read more
Understanding why immunotherapies are highly effective in some patients but fail in many others is one of the top priorities in cancer research — and one of the most challenging puzzles. A research team led by Catherine J. Wu, MD, has uncovered some previously unknown molecular factors affecting donor lymphocyte infusion (DLI), a form of … Read more
In December 2013, Michelle Leonard wasn’t too concerned when she felt a pain in her right chest. “I kind of thought, ‘Well at least it’s the right side, not a big deal,’” she says. But then she developed a fever and decided to go to her primary care physician. Her nurse practitioner sent her for … Read more
As a former volunteer firefighter, Paul Calnan prided himself on being ready for any emergency. He thought nothing could rattle him — until, at age 47, doctors discovered a large, malignant tumor in his liver. The diagnosis was stage IV intrahepatic cholangiocarcinoma, a rare form of bile duct cancer that had presented in Calnan’s liver. … Read more
Cancer vaccines are a form of immunotherapy aimed at enhancing the immune system’s ability to recognize and attack cancer cells, or to protect against certain forms of cancer caused by viruses. Vaccine can help prevent some cancers There are two approved preventive vaccines directed against cancer-causing viruses. Vaccines against cancer-causing or other infectious microbes typically … Read more
Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits. A major reason for the inconsistent results of immunotherapy is a phenomenon known as “T-cell exhaustion” — a weakening or loss of tumor-killing function by T … Read more
Tumors with high mutational burden have a large number of genetic mutations, or misspellings of the genetic code within their cells. Such cancers tend to acquire mutations as a result of exposure to harmful agents such as ultraviolet light or certain chemicals in tobacco. Malignancies that often have a high number of mutations include: Non-small … Read more
The go-to metaphor for cancer drugs known as immune checkpoint inhibitors is a brake-release lever — a means of setting loose an immune system attack on tumor cells. Helpful as it is, the analogy glosses over a highly complex mechanism involving multiple types of immune cells, cell receptors, signals, and responses — so intricate that … Read more
The intriguing case of a man with melanoma tumors that responded in different ways to the same checkpoint-blocking drug has yielded an important clue to the causes of resistance to immunotherapy treatments, according to Dana-Farber researchers. The findings could help guide the use of immunotherapy in individual patients. The 74-year-old patient, described in a report … Read more